典型霍奇金淋巴瘤：LYSA 实用指南

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2024-10-22 DOI:10.1016/j.ejca.2024.115073

Cédric Rossi , Guillaume Manson , Amira Marouf , Aurélie Cabannes-Hamy , Emmanuelle Nicolas-Virelizier , Marie Maerevoet , Marion Alcantara , Lysiane Molina , Antony Ceraulo , Marilyne Poirée , Jean Galtier , Nadia Diop , Caroline Delette , Amandine Segot , Sydney Dubois , Agathe Waultier , Sophie Bernard , Robin Noël , Stéphanie Guidez , Milena Kohn , Hervé Ghesquières

{"title":"典型霍奇金淋巴瘤：LYSA 实用指南","authors":"Cédric Rossi , Guillaume Manson , Amira Marouf , Aurélie Cabannes-Hamy , Emmanuelle Nicolas-Virelizier , Marie Maerevoet , Marion Alcantara , Lysiane Molina , Antony Ceraulo , Marilyne Poirée , Jean Galtier , Nadia Diop , Caroline Delette , Amandine Segot , Sydney Dubois , Agathe Waultier , Sophie Bernard , Robin Noël , Stéphanie Guidez , Milena Kohn , Hervé Ghesquières","doi":"10.1016/j.ejca.2024.115073","DOIUrl":null,"url":null,"abstract":"<div><div>Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management. In this article, we present a comprehensive set of recommendations for the management of HL, encompassing various aspects of diagnosis, risk stratification, evaluation, and treatment. These recommendations are based on the latest evidence-based guidelines, expert consensus opinions, and clinical trial data, aiming to provide clinicians with a practical framework for delivering optimal care to patients with HL.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115073"},"PeriodicalIF":7.6000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines\",\"authors\":\"Cédric Rossi , Guillaume Manson , Amira Marouf , Aurélie Cabannes-Hamy , Emmanuelle Nicolas-Virelizier , Marie Maerevoet , Marion Alcantara , Lysiane Molina , Antony Ceraulo , Marilyne Poirée , Jean Galtier , Nadia Diop , Caroline Delette , Amandine Segot , Sydney Dubois , Agathe Waultier , Sophie Bernard , Robin Noël , Stéphanie Guidez , Milena Kohn , Hervé Ghesquières\",\"doi\":\"10.1016/j.ejca.2024.115073\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management. In this article, we present a comprehensive set of recommendations for the management of HL, encompassing various aspects of diagnosis, risk stratification, evaluation, and treatment. These recommendations are based on the latest evidence-based guidelines, expert consensus opinions, and clinical trial data, aiming to provide clinicians with a practical framework for delivering optimal care to patients with HL.</div></div>\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"213 \",\"pages\":\"Article 115073\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804924012048\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924012048","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

经典霍奇金淋巴瘤（HL）是 B 细胞来源血液恶性肿瘤中的一种独特类型。它具有独特的组织病理学特征，预后一般良好。多年来，随着对其发病机制认识的不断深入、诊断和评估方法的不断完善以及治疗策略的不断改进，HL 的治疗格局发生了显著变化。在本文中，我们为 HL 的治疗提出了一套全面的建议，包括诊断、风险分层、评估和治疗等各个方面。这些建议基于最新的循证指南、专家共识意见和临床试验数据，旨在为临床医生提供一个切实可行的框架，为 HL 患者提供最佳治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines

Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management. In this article, we present a comprehensive set of recommendations for the management of HL, encompassing various aspects of diagnosis, risk stratification, evaluation, and treatment. These recommendations are based on the latest evidence-based guidelines, expert consensus opinions, and clinical trial data, aiming to provide clinicians with a practical framework for delivering optimal care to patients with HL.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.